Bristol Myers Squibb Announces Positive Phase 3 Results for Mezigdomide in Multiple Myeloma on March 11, 2026 CELMoD mezigdomide Multiple Myeloma Myers Squibb Phase 3 Progression-Free Survival SUCCESSOR-2 +